Corbus Pharmaceuticals (CRBP) closed the last trading session at $59.70, gaining 2.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $85.86 indicates a 43.8% upside potential.The average comprises seven short-term price targets ranging from a low of $76 to a high of $105, with a standard deviation of $9.30. While the lowest estimate indicates an increase of 27.3% from the current ...

NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. “With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen,” said Alan F. Holmer, Chairman of th ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Corbus Pharmaceuticals (CRBP) closed the last trading session at $53.60, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $82.67 indicates a 54.2% upside potential.The average comprises six short-term price targets ranging from a low of $76 to a high of $88, with a standard deviation of $4.27. While the lowest estimate indicates an increase of 41.8% from the current pri ...

临床试验 - 公司正在开展CRB-701和CRB-601两款实验性药物的临床试验,CRB-701是一种靶向Nectin-4的新一代抗体偶联药物,CRB-601是一种抑制TGFβ激活的抗整合素单克隆抗体[132,133] - CRB-913是一种高度外周受限的CB1受体逆激动剂,正在进行IND使能研究,预计2025年第一季度开始进行I期临床试验[134] 融资活动 - 公司在2023年5月31日与Jefferies签订了公开市场销售协议,可发行总价值最高1.5亿美元的普通股[135] - 公司需要筹集大量额外资金以继续为CRB-701和CRB-601的临床试验提供资金[154] - 公司可能通过出售普通股或优先股、可转换债务证券、获得信贷额度或其他形式的第三方融资来筹集资金[154] - 公司未来融资的时间和可用性将主要取决于市场状况和临床开发项目的进展[155] 财务状况 - 公司2024年上半年的研发费用为1260万美元,较2023年同期下降500万美元,主要是由于许可费用的减少[144] - 公司2024年上半年的一般及行政费用为800万美元,较2023年同期增加20万美元,基本持平[146] - 公司2024年上半年获得约370万美元的其他收益,主要来自于外国税务机关的研发税收抵免[147] - 截至2024年6月30日,公司拥有1.48亿美元的流动资产和2400万美元的流动负债,流动资金为1.24亿美元[149] - 公司2024年上半年经营活动净现金流出1690万美元,主要用于支付研发费用[150] - 公司2024年上半年投资活动净现金流出1.15亿美元,主要用于购买有价证券[151] - 公司在2024年6月30日结束的六个月内通过发行普通股筹集了约1.415亿美元的融资活动现金[152] - 公司预计截至2024年6月30日的现金、现金等价物和投资约1.47亿美元将足以支持到2027年第三季度的运营和资本需求[153] 许可协议 - 公司与Jenrin、Milky Way、UCSF和CSPC签有许可协议,需支付里程碑付款和特许权使用费[157][159][161][163]

临床试验进展 - 公司在ASCO 2024会议上展示了CRB-701的临床更新数据,显示其在转移性尿路上皮癌和宫颈癌患者中具有持续的安全性差异和令人鼓舞的疗效[2] - CRB-701的1期剂量递增试验正在美国和欧洲进行,预计于2024年第四季度完成[3] - CRB-701在转移性尿路上皮癌和宫颈癌患者中分别显示44%和43%的客观缓解率,78%和86%的疾病控制率[6] - CRB-701至今未观察到剂量限制性毒性,仅出现少量皮疹和周围神经病变,且均已解决[6] - CRB-913是一种高度外周受限的CB1受体逆激动剂,公司计划于2025年第一季度开始1期临床试验[8] - CRB-601是一种高亲和力和选择性的抗αvβ8单克隆抗体,公司计划于2024年第四季度启动1期临床试验[10] 财务状况 - 公司在2024年6月30日拥有1.47亿美元的现金和投资,预计可维持运营至2027年第三季度[13] - 公司在2024年第二季度和2024年8月1日前通过ATM计划筹集了约6.44亿美元的净收益[13] - 公司现金及现金等价物为23,686美元，较上年同期增加72.4%[24] - 公司投资总额为123,339美元，较上年同期大幅增加1,617.5%[24] - 公司总资产为151,979美元，较上年同期增加437.5%[24] - 公司流动负债总额为23,980美元，较上年同期减少24.8%[24] - 公司总负债为26,436美元，较上年同期减少24.9%[24] - 公司股东权益为125,543美元，较上年同期转为正值[24] - 公司发行在外普通股数量为11,498,917股，较上年同期增加159.6%[24] - 公司累计亏损为453,580美元，较上年同期增加3.9%[24] - 公司其他综合收益为负388美元，较上年同期大幅下降[24] - 公司经营租赁负债(流动和非流动)合计为3,975美元，较上年同期减少12.5%[24]

NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events. BTIG Virtual Biotechnology Conference Date: August 5-6, 2024Format: Invitation only, one-on-one investor meetingsNote ...

NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events. BTIG Virtual Biotechnology Conference Date: August 5-6, 2024Format: Invitation only, one-on-one investor meetingsNot ...

Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don’t have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow. More often than not, they will hunker down instead of taking on new, expensive debt. Although it is difficult to predict how these companies with respond to rate cuts but could unleash a torrent of growth. Particularly with undi ...

An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in mUC and 43% ORR and 86% DCR in cervical cancer to date at doses ≥ 1.2mg/Kg No dose limiting toxicities (DLTs) have been observed to date in doses up to and including 4.5 mg/Kg (cohort 7) Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all were resolved Early PK data demonstrate c ...